<DOC>
	<DOCNO>NCT02668315</DOCNO>
	<brief_summary>Allogeneic hematopoietic stem cell transplantation life-saving procedure patient blood cancer , 25 % transplant candidate sibling donor . A matched unrelated donor find 60 % patient number low non-Caucasians . Cord blood ( CB ) , another source stem cell , major advantage unrelated donor include immediate availability , good permissiveness immune mismatch donor transplant recipient , good availability non-Caucasians , less graft versus host disease , complication frequently see transplant negatively affect quality life . Unfortunately , use CB still limit adult small number stem cell . UM171 , molecule hematopoietic stem cell expansion property , show increase cord blood stem cell 13 fold . In trial , Investigators use UM171 treat CB patient need transplant lack acceptable donor.This protocol seek test safety CB cell expand UM171 , determine kinetics engraftment well minimal cord blood unit cell dose expand achieves prompt engraftment .</brief_summary>
	<brief_title>Expanded Cord Blood Patients Need Allogeneic Stem Cell Transplant</brief_title>
	<detailed_description>Investigators propose phase I-II , Canadian multi-center , open-label study UM171 ex vivo expand CB transplant 25 patient need allogeneic hematopoietic stem cell transplantation ( HSCT ) lack Human Leucocyte Antigen ( HLA ) match donor . Investigators key primary secondary objective include : 1 . To establish feasibility expand cord blood unit allogeneic cord blood transplantation . 2 . To establish safety identify unexpected toxicity associate transplantation cord blood cell expand UM171/fed-batch culture system . 3 . To measure kinetics neutrophil platelet recovery . 4 . To determine minimal cord blood unit cell dose ( Total Nucleated Cell ( TNC ) /CD34+ cell ) expand achieves prompt engraftment single cord transplant . Methodology : Patients hematologic malignancy indication allogeneic HSCT lack match unrelated donor receive myeloablative submyeloablative conditioning regimen follow infusion UM171 expand CB graft . Accrual expect last 18 month patient follow 3 year . Expected benefit : Investigators expect expansion UM171/fed-batch safe lead rapid sustain engraftment . This likely decrease high early morbidity/mortality CB HSCT improve access transplant , especially ethnic minority . In addition , low cell dose solve , patient benefit CB 's low risk chronic ( graft versus host disease ) GVHD , major cause morbidity .</detailed_description>
	<criteria>Inclusion 1 . 364 year old ( Pediatric patient become eligible 5 adult patient enrol study receive UM171 expand product ) . 2 . Weight ≥ 12kg 3 . Underlying hematologic malignancy exclude primary myelofibrosis require unrelated donor allogeneic HSC transplant ( define transplant center ) patient lack 8/8 HLA identical donor disease require urgent transplant wait require time identify unrelated donor . 4 . Availability least 3 cord blood HLA match ≥ 4/6 ≥4/8 meeting follow requirement : CB expand : CD34+ cell count 1.04.9 x 10E5/kg cohort 1 , 0.54.9 x 10E5/kg cohort 2 , 0.254.9 x 10E5/kg cohort 3 ; nucleate cell count ≥ 2.0 x 10E7/kg cohort 1 , ≥ 1.5 x 10E7/kg cohort 2 , ≥ 1.25 x 10E7/kg cohort 3 . Non expand cord : TNC count ≥ 2.0 x 10E7/kg CD34 min 1 x 10E5/kg minimum 1.5 x 10E7 TNC/kg 1.8 x 10E5 CD34+ cells/kg . Back cord : TNC count ≥ 1.5 x 10E7/kg CD34 min 1 x 10E5/kg 5 . Left ventricular ejection fraction &gt; 40 % . 6 . Karnofsky score ≥ 70 % 7 . Forced vital capacity ( FVC ) , forced expiratory volume 1 second ( FEV1 ) diffuse capacity correct hemoglobin ( DLCOc ) ≥ 50 % predict 8 . Bilirubin &lt; 2 x upper limit normal ( ULN ) unless felt related Gilbert 's disease hemolysis ; AST ( aspartate aminotransferase ) ALT ( alanine aminotransférase ) ≤ 2.5 x ULN ; alkaline phosphatase ≤ 5 x ULN . 9 . Measured estimated creatinine clearance ≥ 60 ml/min/1.73m2 . Exclusion 1 . Myeloablative transplant within 24 month . 2 . Uncontrolled infection . 3 . Presence malignancy one UCB transplant perform expect survival related malignancy estimate less 75 % 5 year . 4 . HIV positivity . 5 . Hepatitis B C infection measurable viral load . 6 . Liver cirrhosis . 7 . Availability cord ≥ 5 x 105/kg CD34+ cell . 8 . Pregnancy , breastfeed unwillingness use appropriate contraception . 9 . Participation trial investigational agent within 30 day prior entry study . 10 . Patient unable give inform consent unable comply treatment protocol include appropriate supportive care , followup , test . 11 . Any abnormal condition laboratory result consider principal investigator capable alter patient condition study outcome .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>